Table 1 Summary of patient information from two cohorts in this study.
Characteristics | Cohort 1 (n = 297) | Cohort 2 (n = 169) | P value |
|---|---|---|---|
Mean age (min–max) (years) | 67.3 (31–90) | 68.8 (25–90) | 0.68 |
Gender | 0.93 | ||
Male | 152 (51.2%) | 88 (52.1%) | |
Female | 145 (48.8%) | 81 (47.9%) | |
Neoadjuvant treatment | 0.54 | ||
Yes | 2 (0.7%) | 0 | |
No | 295 (99.3%) | 169 (100%) | |
Perforation status | NA | ||
No perforation | NA | 160 (94.7%) | |
Perforation | NA | 9 (5.3%) | |
ND | 297 (100%) | 0 | |
Tumor location | 2.92 × 10−17 | ||
Right colon | 144 (48.5%) | 73 (43.2%) | |
Left colon | 87 (29.3%) | 62 (36.7%) | |
Recto-sigmoid junction/rectum | 4 (1.3%) | 33 (19.5%) | |
Colon NOS | 62 (20.9%) | 1 (0.6%) | |
Tumor grade | NA | ||
Low-grade | NA | 158 (93.5%) | |
High-grade | NA | 11 (6.5%) | |
ND | 297 (100%) | NA | |
Lymphovascular and/or perineural invasion (VELIPI) | 9.53 × 10−9 | ||
Yes | 131 (44.1%) | 62 (36.7%) | |
No | 61 (20.5%) | 104 (61.5%) | |
ND | 105 (35.4%) | 3 (1.8%) | |
TNM stage | 0.75 | ||
II | 171 (57.6%) | 94 (55.6%) | |
III | 126 (42.4%) | 75 (44.4%) | |
Lymph nodes examined | 0.13 | ||
<12 | 27 (9.1%) | 25 (14.8%) | |
≥12 | 254 (85.5%) | 144 (85.2%) | |
ND | 16 (5.4%) | NA | |
MMR status (IHC) | 0.99 | ||
MSS | 184 (62%) | 141 (83.4%) | |
MSI | 38 (12.8%) | 28 (16.6%) | |
ND | 75 (25.2%) | NA | |
CDX2 status (IHC) | NA | ||
CDX2-negative | NA | 16 (9.5%) | |
CDX2-positive | NA | 153 (90.5%) | |
ND | 297 (100%) | NA | |
Adjuvant chemotherapy | NA | ||
Yes | 96 (32.3%) | NA | |
No | 151 (50.9%) | NA | |
ND | 50 (16.8%) | 169 (100%) | |
Mean follow-up duration (minimum–maximum) (years) | 2.6 (0–12.3) | 5.6 (0–12) | 0.76 |
Progression-free interval (PFI)/Disease-free survival (DFS) | 0.73 | ||
Progression | 67 (22.6%) | 41 (24.3%) | |
No progression | 230 (77.4%) | 127 (75.1%) | |
ND | NA | 1 (0.6%) | |
Overall survival | 0.26 | ||
Dead | 53 (17.8%) | 38 (22.5%) | |
Alive | 244 (82.2%) | 130 (76.9%) | |
ND | NA | 1 (0.6%) |
